DVA vs PROK
DVA: Leading US dialysis and integrated kidney care provider serving end-stage renal disease patients across clinical centers, home-based settings, and transplant support globally. PROK: ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in Phase 3 trials with FDA RMAT designation.
Side-by-side fundamentals
| Metric | DVA | PROK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $232.08 | $1.53 | |
| Market cap as of 2026-07-23 | $15.0B | $462M | |
| P/E as of 2026-07-23 | 19.22 | n/a | |
| PEG as of 2026-07-23 | 7.29 | n/a | |
| Net margin as of 2026-07-23 | +5.7% | -8131.5% | DVA higher |
| Gross margin as of 2026-07-23 | +32.5% | n/a | |
| Operating margin as of 2026-07-23 | +15.0% | -18959.7% | DVA higher |
| ROE as of 2026-07-23 | +181.2% | -28.1% | DVA higher |
| ROA as of 2026-07-23 | +4.5% | -21.4% | DVA higher |
| Debt / equity as of 2026-07-23 | 77.99 | 5.40 | PROK lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.7% | +190.5% | PROK higher |
| Revenue CAGR (3y) SEC XBRL | +5.5% | n/a | |
| Beta as of 2026-07-23 | 0.88 | 1.81 | |
| 1-year return as of 2026-07-22 close | +58.9% | -49.8% | DVA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.